NCT02086734View on ClinicalTrials.gov

Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2018

Conditions
Metastatic Renal Cancer
Interventions
OTHER

Perfusion-CT

"1. Baseline Perfusion CT-Scan (before AAT)~2. Follow-Up I Perfusion-CT Scan 7 days after start with AAT~3. Follow-Up II Perfusion-CT Scan 8 weeks after start with AAT"

Trial Locations (1)

81377

Urologische Klinik und Poliklinik der Universität München, München

All Listed Sponsors
lead

Ludwig-Maximilians - University of Munich

OTHER

NCT02086734 - Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter